Patents by Inventor Pieter Rutter Cullis

Pieter Rutter Cullis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220074925
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: April 2, 2021
    Publication date: March 10, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Publication number: 20200225215
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: June 14, 2019
    Publication date: July 16, 2020
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Publication number: 20180209963
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: September 1, 2017
    Publication date: July 26, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Publication number: 20160274089
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: October 30, 2015
    Publication date: September 22, 2016
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Publication number: 20140295449
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: October 21, 2013
    Publication date: October 2, 2014
    Applicant: Tekmira Pharmaceuticals, Inc.
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Home, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Publication number: 20120225434
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 6, 2012
    Applicants: ALNYLAM PHARMACEUTICALS, INC., The University of British Columbia, Tekmira Pharmaceuticals Corporation
    Inventors: Marco A. CIUFOLINI, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Publication number: 20110097720
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: December 31, 2008
    Publication date: April 28, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, De Fougerolles Antonin, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis